

Jerome Galon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2219760/publications.pdf>

Version: 2024-02-01

216
papers

51,148
citations

5126

86
h-index

2402

204
g-index

231
all docs

231
docs citations

231
times ranked

57212
citing authors

#	ARTICLE	IF	CITATIONS
1	Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome. <i>Science</i> , 2006, 313, 1960-1964.	6.0	5,356
2	ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. <i>Bioinformatics</i> , 2009, 25, 1091-1093.	1.8	5,348
3	The immune contexture in human tumours: impact on clinical outcome. <i>Nature Reviews Cancer</i> , 2012, 12, 298-306.	12.8	3,873
4	Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer. <i>Immunity</i> , 2013, 39, 782-795.	6.6	2,983
5	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. <i>Nature Reviews Drug Discovery</i> , 2019, 18, 197-218.	21.5	2,005
6	Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer. <i>New England Journal of Medicine</i> , 2005, 353, 2654-2666.	13.9	1,860
7	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet, The</i> , 2018, 391, 2128-2139.	6.3	1,487
8	Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. <i>Cell</i> , 1999, 97, 133-144.	13.5	1,271
9	Towards the introduction of the "Immunoscore"™ in the classification of malignant tumours. <i>Journal of Pathology</i> , 2014, 232, 199-209.	2.1	1,151
10	Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer. <i>Cancer Research</i> , 2011, 71, 1263-1271.	0.4	986
11	CluePedia Cytoscape plugin: pathway insights using integrated experimental and <i>in silico</i> data. <i>Bioinformatics</i> , 2013, 29, 661-663.	1.8	958
12	Histopathologic-Based Prognostic Factors of Colorectal Cancers Are Associated With the State of the Local Immune Reaction. <i>Journal of Clinical Oncology</i> , 2011, 29, 610-618.	0.8	864
13	The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy. <i>Nature Reviews Cancer</i> , 2020, 20, 662-680.	12.8	860
14	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. <i>Nature Reviews Cancer</i> , 2015, 15, 668-679.	12.8	839
15	In Situ Cytotoxic and Memory T Cells Predict Outcome in Patients With Early-Stage Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5944-5951.	0.8	822
16	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016, 44, 698-711.	6.6	814
17	The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. <i>Immunity</i> , 2013, 39, 11-26.	6.6	700
18	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolimmunology</i> , 2014, 3, e955691.	2.1	686

#	ARTICLE	IF	CITATIONS
19	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	1.8	676
20	The immune score as a new possible approach for the classification of cancer. <i>Journal of Translational Medicine</i> , 2012, 10, 1.	1.8	656
21	Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. <i>FASEB Journal</i> , 2002, 16, 61-71.	0.2	510
22	From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer. <i>Current Opinion in Immunology</i> , 2013, 25, 261-267.	2.4	444
23	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. <i>Genome Biology</i> , 2015, 16, 64.	3.8	433
24	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	0.8	395
25	The Adaptive Immunologic Microenvironment in Colorectal Cancer: A Novel Perspective: Figure 1.. <i>Cancer Research</i> , 2007, 67, 1883-1886.	0.4	386
26	The tumor microenvironment and Immunoscore are critical determinants of dissemination to distant metastasis. <i>Science Translational Medicine</i> , 2016, 8, 327ra26.	5.8	360
27	Tumor Immunology and Tumor Evolution: Intertwined Histories. <i>Immunity</i> , 2020, 52, 55-81.	6.6	357
28	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , 2000, 95, 3223-3231.	0.6	356
29	Prognostic and Predictive Impact of Intra- and Peritumoral Immune Infiltrates. <i>Cancer Research</i> , 2011, 71, 5601-5605.	0.4	341
30	The Tumor-Necrosis-Factor Receptor-associated Periodic Syndrome: New Mutations in TNFRSF1A, Ancestral Origins, Genotype-Phenotype Studies, and Evidence for Further Genetic Heterogeneity of Periodic Fevers. <i>American Journal of Human Genetics</i> , 2001, 69, 301-314.	2.6	328
31	Evolution of Metastases in Space and Time under Immune Selection. <i>Cell</i> , 2018, 175, 751-765.e16.	13.5	322
32	Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 1891-1899.	3.2	298
33	Biomolecular Network Reconstruction Identifies T-Cell Homing Factors Associated With Survival in Colorectal Cancer. <i>Gastroenterology</i> , 2010, 138, 1429-1440.	0.6	280
34	Implications of the tumor immune microenvironment for staging and therapeutics. <i>Modern Pathology</i> , 2018, 31, 214-234.	2.9	278
35	From mice to humans: developments in cancer immunoediting. <i>Journal of Clinical Investigation</i> , 2015, 125, 3338-3346.	3.9	271
36	Coordination of Intratumoral Immune Reaction and Human Colorectal Cancer Recurrence. <i>Cancer Research</i> , 2009, 69, 2685-2693.	0.4	262

#	ARTICLE	IF	CITATIONS
37	The Immunoscore: Colon Cancer and Beyond. <i>Clinical Cancer Research</i> , 2020, 26, 332-339.	3.2	255
38	Cancer immunology analysis of host and tumor factors for personalized medicine. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 711-719.	12.5	251
39	Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases. <i>Oncolimmunology</i> , 2016, 5, e1057388.	2.1	239
40	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolimmunology</i> , 2015, 4, e1008866.	2.1	237
41	Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes. <i>Journal of Immunology</i> , 2000, 164, 1768-1774.	0.4	228
42	Immune evasion before tumour invasion in early lung squamous carcinogenesis. <i>Nature</i> , 2019, 571, 570-575.	13.7	227
43	TNFRSF1A mutations and autoinflammatory syndromes. <i>Current Opinion in Immunology</i> , 2000, 12, 479-486.	2.4	224
44	Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy. <i>Cancer Research</i> , 2015, 75, 3446-3455.	0.4	210
45	The Link between the Multiverse of Immune Microenvironments in Metastases and the Survival of Colorectal Cancer Patients. <i>Cancer Cell</i> , 2018, 34, 1012-1026.e3.	7.7	209
46	Trial watch. <i>Oncolimmunology</i> , 2012, 1, 1323-1343.	2.1	203
47	Comprehensive Intrametastatic Immune Quantification and Major Impact of Immunoscore on Survival. <i>Journal of the National Cancer Institute</i> , 2018, 110, 97-108.	3.0	199
48	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. <i>Oncolimmunology</i> , 2012, 1, 894-907.	2.1	194
49	Immune Infiltration in Human Cancer: Prognostic Significance and Disease Control. <i>Current Topics in Microbiology and Immunology</i> , 2010, 344, 1-24.	0.7	193
50	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 699-739.	2.1	184
51	Functional Network Pipeline Reveals Genetic Determinants Associated with in Situ Lymphocyte Proliferation and Survival of Cancer Patients. <i>Science Translational Medicine</i> , 2014, 6, 228ra37.	5.8	181
52	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. , 2017, 5, 44.		181
53	Trial watch. <i>Oncolimmunology</i> , 2013, 2, e24612.	2.1	175
54	Tumor immunosurveillance in human cancers. <i>Cancer and Metastasis Reviews</i> , 2011, 30, 5-12.	2.7	170

#	ARTICLE	IF	CITATIONS
55	Stat4 Is Expressed in Activated Peripheral Blood Monocytes, Dendritic Cells, and Macrophages at Sites of Th1-Mediated Inflammation. <i>Journal of Immunology</i> , 2000, 164, 4659-4664.	0.4	168
56	Tissue-resident FOLR2+ macrophages associate with CD8+ T cell infiltration in human breast cancer. <i>Cell</i> , 2022, 185, 1189-1207.e25.	13.5	166
57	Natural immunity to cancer in humans. <i>Current Opinion in Immunology</i> , 2010, 22, 215-222.	2.4	153
58	Trial watch. <i>Oncolmunology</i> , 2013, 2, e23510.	2.1	153
59	Trial watch. <i>Oncolmunology</i> , 2012, 1, 1111-1134.	2.1	152
60	Trial watch. <i>Oncolmunology</i> , 2013, 2, e25771.	2.1	150
61	Rational bases for the use of the Immunoscore in routine clinical settings as a prognostic and predictive biomarker in cancer patients. <i>International Immunology</i> , 2016, 28, 373-382.	1.8	143
62	Positive Effects of Glucocorticoids on T Cell Function by Up-Regulation of IL-7 Receptor α . <i>Journal of Immunology</i> , 2002, 168, 2212-2218.	0.4	142
63	T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells. <i>Cancer Cell</i> , 2016, 30, 377-390.	7.7	141
64	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	1.8	139
65	Trial Watch. <i>Oncolmunology</i> , 2014, 3, e27878.	2.1	134
66	Trial Watch. <i>Oncolmunology</i> , 2013, 2, e25238.	2.1	132
67	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	0.8	130
68	The Immune Microenvironment of Human Tumors: General Significance and Clinical Impact. <i>Cancer Microenvironment</i> , 2013, 6, 117-122.	3.1	119
69	Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer. <i>Nature Medicine</i> , 2020, 26, 919-931.	15.2	118
70	Trial watch. <i>Oncolmunology</i> , 2012, 1, 1557-1576.	2.1	110
71	Compromised nuclear envelope integrity drives TREX1-dependent DNA damage and tumor cell invasion. <i>Cell</i> , 2021, 184, 5230-5246.e22.	13.5	109
72	Glucocorticoids and Inflammation Revisited: The State of the Art. <i>NeuroImmunoModulation</i> , 2002, 10, 247-260.	0.9	107

#	ARTICLE	IF	CITATIONS
73	Pancreatic Ductal Adenocarcinoma: A Strong Imbalance of Good and Bad Immunological Cops in the Tumor Microenvironment. <i>Frontiers in Immunology</i> , 2018, 9, 1044.	2.2	107
74	The essential role of the in situ immune reaction in human colorectal cancer. <i>Journal of Leukocyte Biology</i> , 2008, 84, 981-987.	1.5	106
75	Trial watch. <i>Oncolmmunology</i> , 2012, 1, 179-188.	2.1	104
76	The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. <i>Journal of Translational Medicine</i> , 2013, 11, 54.	1.8	104
77	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1088631.	2.1	104
78	Trial Watch: Monoclonal antibodies in cancer therapy. <i>Oncolmmunology</i> , 2012, 1, 28-37.	2.1	103
79	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1008814.	2.1	102
80	Trial Watch. <i>Oncolmmunology</i> , 2013, 2, e26621.	2.1	101
81	Trial Watch. <i>Oncolmmunology</i> , 2014, 3, e27297.	2.1	99
82	The prognostic impact of anti-cancer immune response: a novel classification of cancer patients. <i>Seminars in Immunopathology</i> , 2011, 33, 335-340.	2.8	97
83	The immune landscape of human tumors. <i>Oncolmmunology</i> , 2014, 3, e27456.	2.1	97
84	Trial Watch: Peptide-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e974411.	2.1	97
85	Trial Watch:. <i>Oncolmmunology</i> , 2014, 3, e28694.	2.1	95
86	Germline genetic contribution to the immune landscape of cancer. <i>Immunity</i> , 2021, 54, 367-386.e8.	6.6	95
87	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e23803.	2.1	92
88	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e22789.	2.1	92
89	Trial Watch“Oncolytic viruses and cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1117740.	2.1	88
90	Trial Watch. <i>Oncolmmunology</i> , 2012, 1, 493-506.	2.1	86

#	ARTICLE	IF	CITATIONS
91	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e25595.	2.1	83
92	Comprehensive functional analysis of large lists of genes and proteins. <i>Journal of Proteomics</i> , 2018, 171, 2-10.	1.2	80
93	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e29179.	2.1	76
94	Immune-related gene signatures predict the outcome of neoadjuvant chemotherapy. <i>Oncolimmunology</i> , 2014, 3, e27884.	2.1	74
95	Trial Watch. <i>Oncolimmunology</i> , 2012, 1, 306-315.	2.1	70
96	Trial Watch. <i>Oncolimmunology</i> , 2014, 3, e27048.	2.1	69
97	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. , 2016, 4, 15.		67
98	A Diagnostic Biopsy-Adapted Immunoscore Predicts Response to Neoadjuvant Treatment and Selects Patients with Rectal Cancer Eligible for a Watch-and-Wait Strategy. <i>Clinical Cancer Research</i> , 2020, 26, 5198-5207.	3.2	66
99	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. <i>Oncolimmunology</i> , 2016, 5, e1214790.	2.1	64
100	Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. , 2019, 7, 131.		64
101	Trial watch: Dendritic cell-based anticancer therapy. <i>Oncolimmunology</i> , 2014, 3, e963424.	2.1	62
102	Soluble FC γ 3 receptors. <i>Journal of Leukocyte Biology</i> , 1993, 54, 504-512.	1.5	59
103	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e24238.	2.1	58
104	Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response. , 2020, 8, e000617.		57
105	Validation of the Immunoscore (IM) as a prognostic marker in stage I/II/III colon cancer: Results of a worldwide consortium-based analysis of 1,336 patients.. <i>Journal of Clinical Oncology</i> , 2016, 34, 3500-3500.	0.8	57
106	Toward integrative cancer immunotherapy: targeting the tumor microenvironment. <i>Journal of Translational Medicine</i> , 2012, 10, 70.	1.8	53
107	Trial Watch“Immunostimulation with cytokines in cancer therapy. <i>Oncolimmunology</i> , 2016, 5, e1115942.	2.1	52
108	Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 1428-1433.	3.3	51

#	ARTICLE	IF	CITATIONS
109	Trial watch. <i>Oncolimmunology</i> , 2014, 3, e29030.	2.1	51
110	Trial Watch: Lenalidomide-based immunochemotherapy. <i>Oncolimmunology</i> , 2013, 2, e26494.	2.1	50
111	Tumor Microenvironment and Immunotherapy: The Whole Picture Is Better Than a Glimpse. <i>Immunity</i> , 2015, 43, 631-633.	6.6	50
112	Affinity of the interaction between Fcγ receptor type III (FcγRIII) and monomeric human IgG subclasses. Role of FcγRIII glycosylation. <i>European Journal of Immunology</i> , 1997, 27, 1928-1932.	1.6	49
113	Trial Watch. <i>Oncolimmunology</i> , 2013, 2, e24850.	2.1	49
114	Automated exploration of gene ontology term and pathway networks with ClueGO-REST. <i>Bioinformatics</i> , 2019, 35, 3864-3866.	1.8	48
115	Immunoscore and its introduction in clinical practice. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 64, 152-161.	0.4	48
116	Trial watch: Tumor-targeting monoclonal antibodies for oncological indications. <i>Oncolimmunology</i> , 2015, 4, e985940.	2.1	47
117	Adrenal cortical activation in murine colitis. <i>Gastroenterology</i> , 2000, 119, 1560-1568.	0.6	46
118	Immunosurveillance in human non-viral cancers. <i>Current Opinion in Immunology</i> , 2011, 23, 272-278.	2.4	46
119	Trial Watch "Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolimmunology</i> , 2016, 5, e1149674.	2.1	46
120	Frameshift mutations, neoantigens and tumor-specific CD8 ⁺ T cells in microsatellite unstable colorectal cancers. <i>Oncolimmunology</i> , 2016, 5, e1115943.	2.1	45
121	Analytical validation of the Immunoscore and its associated prognostic value in patients with colon cancer. , 2020, 8, e000272.		43
122	Characterization of anti-CD19 chimeric antigen receptor (CAR) T cell-mediated tumor microenvironment immune gene profile in a multicenter trial (ZUMA-1) with axicabtagene ciloleucel (axi-cel, KTE-C19).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3025-3025.	0.8	42
123	Regulation of production of soluble Fcγ receptors type III in normal and pathological conditions. <i>Immunology Letters</i> , 1999, 68, 125-134.	1.1	41
124	Identification of the cleavage site involved in production of plasma soluble Fc gamma receptor type III (CD16). <i>European Journal of Immunology</i> , 1998, 28, 2101-2107.	1.6	40
125	Bioinformatics for cancer immunology and immunotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1885-1903.	2.0	40
126	Trial Watch: Radioimmunotherapy for oncological indications. <i>Oncolimmunology</i> , 2014, 3, e954929.	2.1	40

#	ARTICLE	IF	CITATIONS
127	Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2625-2629.	3.3	39
128	Meta-analysis of organ-specific differences in the structure of the immune infiltrate in major malignancies. Oncotarget, 2015, 6, 11894-11909.	0.8	39
129	Do glucocorticoids participate in thymocyte development?. Trends in Immunology, 2000, 21, 644-645.	7.5	37
130	Trial Watch. Oncoimmunology, 2014, 3, e28185.	2.1	36
131	Contribution of Immunoscore and Molecular Features to Survival Prediction in Stage III Colon Cancer. JNCI Cancer Spectrum, 2020, 4, pkaa023.	1.4	36
132	A New Set of Monoclonal Antibodies Against Human Fc γ RII (CD32) and Fc γ RIII (CD16): Characterization and Use in Various Assays. Hybridoma, 1997, 16, 519-528.	0.9	35
133	Hierarchy of Protein Tyrosine Kinases in Interleukin-2 (IL-2) Signaling: Activation of Syk Depends on Jak3; However, Neither Syk nor Lck Is Required for IL-2-Mediated STAT Activation. Molecular and Cellular Biology, 2000, 20, 4371-4380.	1.1	35
134	Soluble CD16 Inhibits CR3 (CD11b/CD18)-Mediated Infection of Monocytes/Macrophages by Opsonized Primary R5 HIV-1. Journal of Immunology, 2001, 166, 3377-3383.	0.4	32
135	Trial Watch. Oncoimmunology, 2014, 3, e28344.	2.1	31
136	Trial Watch: Adoptive cell transfer for oncological indications. Oncoimmunology, 2015, 4, e1046673.	2.1	29
137	Safety, Antitumor Activity, and T-cell Responses in a Dose-Ranging Phase I Trial of the Oncolytic Peptide LTX-315 in Patients with Solid Tumors. Clinical Cancer Research, 2021, 27, 2755-2763.	3.2	29
138	Modulation of tumor growth by inhibitory Fc γ receptor expressed by human melanoma cells. Journal of Clinical Investigation, 2002, 110, 1549-1557.	3.9	29
139	Evolution of Mutational Landscape and Tumor Immune-Microenvironment in Liver Oligo-Metastatic Colorectal Cancer. Cancers, 2020, 12, 3073.	1.7	28
140	Ligands and biological activities of soluble Fc γ receptors. Immunology Letters, 1995, 44, 175-181.	1.1	26
141	Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells. Blood, 2005, 105, 1632-1639.	0.6	26
142	Trial watch: Naked and vectored DNA-based anticancer vaccines. Oncoimmunology, 2015, 4, e1026531.	2.1	26
143	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	3.2	26
144	Regulation of CTL Infiltration Within the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2017, 1036, 33-49.	0.8	25

#	ARTICLE	IF	CITATIONS
145	The consensus immunoscore: toward a new classification of colorectal cancer. <i>Oncolimmunology</i> , 2020, 9, 1789032.	2.1	25
146	Prognostic assessment of resected colorectal liver metastases integrating pathological features, <i>RAS</i> mutation and Immunoscore. <i>Journal of Pathology: Clinical Research</i> , 2021, 7, 27-41.	1.3	24
147	Genetic trajectory and immune microenvironment of lung-specific oligometastatic colorectal cancer. <i>Cell Death and Disease</i> , 2020, 11, 275.	2.7	21
148	Soluble Fc γ 3 Receptors: Interaction with Ligands and Biological Consequences. <i>International Reviews of Immunology</i> , 1997, 16, 87-111.	1.5	19
149	Additional Support for the Introduction of Immune Cell Quantification in Colorectal Cancer Classification. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw033.	3.0	19
150	Interim analysis of the AVETUXIRI Trial: Avelumab combined with cetuximab and irinotecan for treatment of refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) – A proof of concept, open-label, nonrandomized phase IIa study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 80-80.	0.8	18
151	Phenotyping of tumor infiltrating immune cells using mass-cytometry (CyTOF). <i>Methods in Enzymology</i> , 2020, 632, 339-368.	0.4	17
152	Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction. <i>BMC Genomics</i> , 2010, 11, S7.	1.2	16
153	The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions. <i>Oncolimmunology</i> , 2020, 9, 1812221.	2.1	15
154	Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.. <i>Journal of Clinical Oncology</i> , 2019, 37, 487-487.	0.8	15
155	Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ. <i>Methods in Enzymology</i> , 2020, 635, 51-66.	0.4	14
156	Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer. <i>Cancers</i> , 2021, 13, 1281.	1.7	14
157	Information technology solutions for integration of biomolecular and clinical data in the identification of new cancer biomarkers and targets for therapy. , 2010, 128, 488-498.		13
158	Immunoscore assay for the immune classification of solid tumors: Technical aspects, improvements and clinical perspectives. <i>Methods in Enzymology</i> , 2020, 636, 109-128.	0.4	13
159	The gene for familial Mediterranean fever, MEFV, is expressed in early leukocyte development and is regulated in response to inflammatory mediators. <i>Blood</i> , 2000, 95, 3223-3231.	0.6	13
160	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017,) Tj ETQq0 0 0 rgBT, Overlock		12
161	Preoperative treatment to modify the immune microenvironment of liver colorectal metastases.. <i>Journal of Clinical Oncology</i> , 2015, 33, 602-602.	0.8	12
162	Modulation of tumor growth by inhibitory Fc γ 3 receptor expressed by human melanoma cells. <i>Journal of Clinical Investigation</i> , 2002, 110, 1549-1557.	3.9	12

#	ARTICLE	IF	CITATIONS
163	Tumor-Infiltrating Lymphocytes (TILs) in Early Breast Cancer Patients: High CD3+, CD8+, and Immunoscore Are Associated with a Pathological Complete Response. <i>Cancers</i> , 2022, 14, 2525.	1.7	12
164	Presentation of Antigen in Immune Complexes Is Boosted by Soluble Bacterial Immunoglobulin Binding Proteins. <i>Journal of Experimental Medicine</i> , 1999, 189, 1217-1228.	4.2	11
165	31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. , 2016, 4, .		11
166	Usefulness and robustness of Immunoscore for personalized management of cancer patients. <i>Oncolmunology</i> , 2020, 9, 1832324.	2.1	11
167	No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study. <i>Oncolmunology</i> , 2020, 9, 1826132.	2.1	10
168	The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival. <i>Cancers</i> , 2021, 13, 494.	1.7	10
169	License to kill: microsatellite instability and immune contexture. <i>Oncolmunology</i> , 2021, 10, 1905935.	2.1	10
170	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. <i>Frontiers in Immunology</i> , 2011, 2, 66.	2.2	9
171	hSMG-1 is a granzyme B-associated stress-responsive protein kinase. <i>Journal of Molecular Medicine</i> , 2011, 89, 411-421.	1.7	9
172	Multiverse of immune microenvironment in metastatic colorectal cancer. <i>Oncolmunology</i> , 2020, 9, 1824316.	2.1	9
173	Evasion before invasion: Pre-cancer immunosurveillance. <i>Oncolmunology</i> , 2021, 10, 1912250.	2.1	9
174	Precision immunity: Immunoscore and neoadjuvant treatment in bladder cancer. <i>Oncolmunology</i> , 2021, 10, 1888488.	2.1	9
175	Memory T-Cell Responses and Survival in Human Cancer: Remember to Stay Alive. <i>Advances in Experimental Medicine and Biology</i> , 2010, 684, 166-177.	0.8	9
176	Association of immune markers and Immunoscore with survival of stage III colon carcinoma (CC) patients (pts) treated with adjuvant FOLFOX: NCCTG N0147 (Alliance).. <i>Journal of Clinical Oncology</i> , 2017, 35, 3579-3579.	0.8	9
177	Regulation of CD44 Isoform Expression and CD44-Mediated Signaling in Human Dendritic Cells. <i>Advances in Experimental Medicine and Biology</i> , 1997, 417, 83-90.	0.8	8
178	Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147); Tj ETQq0 0 0 rgB /Overlock 10 Tf 5		8
179	Validation of the Immunoscore prognostic value in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA France cohort study (PRODIGE-GERCOR).. <i>Journal of Clinical Oncology</i> , 2019, 37, 3513-3513.	0.8	8
180	Tumor spread or siege immunity: dissemination to distant metastasis or not. <i>Oncolmunology</i> , 2021, 10, 1919377.	2.1	7

#	ARTICLE	IF	CITATIONS
181	Cutting it Out: Developing Effective Immunotherapies for Patients With Colorectal Cancer. Journal of Immunotherapy, 2021, 44, 49-62.	1.2	7
182	Expand to shield: IL-15 and <i>in situ</i> lymphocytic proliferation. OncoImmunology, 2021, 10, 1886726.	2.1	6
183	Comparison of Immune Response Assessment in Colon Cancer by Immunoscore (Automated Digital) Tj ETQq1 1 0.784314 rgBT /Over	1.7	6
184	Immune sunrise: from the immunome to the cancer immune landscape. OncoImmunology, 2022, 11, 2019896.	2.1	5
185	Immunity to live: an immunopathoscore using the consensus Immunoscore to best define the risk of recurrence and death in stage IV metastatic patients. OncoImmunology, 2020, 9, 1826133.	2.1	4
186	Metastasis immune-based scores predict patient survival. OncoImmunology, 2020, 9, 1806000.	2.1	4
187	The Role of the Immune Infiltrate in Distinct Cancer Types and Its Clinical Implications. Cancer Treatment and Research, 2020, 180, 197-211.	0.2	4
188	Perspectives in Immunotherapy: meeting report from the Immunotherapy Bridge, December 1st-2nd, 2021. Journal of Translational Medicine, 2022, 20, .	1.8	4
189	Association of pretreatment (preTx) tumor characteristics and clinical outcomes following second-line (2L) axicabtagene ciloleucel (axi-cel) versus standard of care (SOC) in patients (pts) with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).. Journal of Clinical Oncology, 2022, 40, 7565-7565.	0.8	4
190	Focus on the target: the tumor microenvironment, Society for Immunotherapy of Cancer Annual Meeting Workshop, October 24th-25th 2012. , 2013, 1, 9.		3
191	Quantifying Immunoscore performance – Authors' reply. Lancet, The, 2018, 392, 1624-1625.	6.3	3
192	The Great Debate at – Immunotherapy Bridge™, Naples, December 5, 2019. , 2020, 8, e000921.		3
193	The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions. OncoImmunology, 2020, 9, 1796003.	2.1	3
194	Specific adaptive immune pattern induced by NBTXR3 exposed to radiation therapy in soft tissue sarcoma (STS) patients.. Journal of Clinical Oncology, 2017, 35, e14615-e14615.	0.8	3
195	The –Immunoscore–in rectal cancer: could we search quality beyond quantity of life?. Oncotarget, 2022, 13, 18-31.	0.8	3
196	Hafnium oxide nanoparticle activated by radiotherapy to generate an anti-tumor immune response.. Journal of Clinical Oncology, 2018, 36, e15149-e15149.	0.8	2
197	Inhibition of TH1 immune response by glucocorticoids: Dexamethasone inhibits IL-12-induced stat4 phosphorylation in T lymphocytes. Gastroenterology, 2000, 118, A790-A791.	0.6	1
198	779 CXCL13-CXCR5 Signaling Is Required for the Anti-Tumor Immune Response in Colorectal Cancer. Gastroenterology, 2014, 146, S-131.	0.6	1

#	ARTICLE	IF	CITATIONS
199	30: From the immune contexture to the Immunoscore in cancer. European Journal of Cancer, 2014, 50, S8.	1.3	1
200	Society for immunotherapy of cancer (SITC) statement on the proposed changes to the common rule. , 2016, 4, 37.		1
201	Prognostic utility of immune markers and validation of Immunoscore in stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance). Annals of Oncology, 2017, 28, iii153.	0.6	1
202	Clinical Response in ZUMA-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma, May Be Influenced by Characteristics of the Pretreatment Tumor Microenvironment (TME). Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S281.	0.2	1
203	Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd,) Tj ETQq1 1.0.784314 rgBT /Ov	1.8	1
204	Characterization of the immune microenvironment of synchronous primary tumor and liver colorectal metastases.. Journal of Clinical Oncology, 2015, 33, 3610-3610.	0.8	1
205	Cytokines et cellules dendritiques.. Medecine/Sciences, 1998, 14, 429.	0.0	1
206	Abstract 1419: Characterization of the evolution of immune response in lung squamous carcinogenesis. , 2016, , .		1
207	Prognostic and predictive value of the Immunoscore in stage III colon cancer patients treated with mFOLFOX6 (three versus six months) in the prospective IDEA France cohort study (PRODIGE-GERCOR).. Journal of Clinical Oncology, 2020, 38, 10-10.	0.8	1
208	Janus Kinases and STAT Family Transcription Factors: Their Role in the Function and Development of Lymphoid Cells. , 0, , 229-254.		0
209	Functional and morphological adrenal changes in TNBS-induced colitis. Gastroenterology, 2000, 118, A343.	0.6	0
210	Positive effects of glucocorticoids on T cell function and development by upregulation of interleukin-7 receptor α . Gastroenterology, 2001, 120, A314-A315.	0.6	0
211	Integrating Biomolecular and Clinical Data for Cancer Research: Concepts and Challenges. , 2012, , 159-172.		0
212	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. , 2014, , 37-51.		0
213	Prognostic association of FoxP3 regulatory T cells with tumor infiltrating CD8 cytotoxic T cells quantified on resected liver colorectal metastases (LCM).. Journal of Clinical Oncology, 2015, 33, e14643-e14643.	0.8	0
214	Abstract A114: Towards personalized cellular adoptive immunotherapy targeting tumor specific neo-antigens in microsatellite unstable colorectal cancers. , 2016, , .		0
215	Abstract 590: A new standardized CD8 and PD-L1 dual assay. , 2017, , .		0
216	Abstract IA12: Integrative genomics and immune contexture approach to immuno-oncology. , 2018, , .		0